The Next-Gen FISH™ reagents are designed for identifying genomic aberrations in FFPE tissues, bone marrow, aspirates and blood specimens. The Next-Gen FISH™ tools are genomic-based reagents and fluorescent in situ hybridization (“FISH”) probes for aiding the study and understanding of numerous cancers both hematologic and solid tumors. The combination of our novel FISH Probe technology with cell isolation techniques as well as proprietary patent pending platform technology that provides unprecedented analytical accuracy for Formalin Fixed, Paraffin Embedded (FFPE) specimens has raised the bar on performing more precise analysis for the chromosomal chaos evident in specific cells of interest.

Innovations in FISH

Our patent pending, Deletion Detection Probe™ (Del-TECT™) and FFPE technology platforms are able to detect genomic changes with unprecedented accuracy. Novel, Next-GEN FISH Probe™ technology distinguishes our FISH probes from all others available.

A proprietary FISH probe panel comprising a targeted set of unique color-coded FISH probes useful for stratifying genomic aberrations more precisely.


CymoGen Dx probes use a proprietary fluorescent labeling system made under GMP in our USA facility located in Irvine, California.

Intellectual Property
The CymoGen Dx Deletion Detection Probe™ (del-TECT™) technology and Formalin Fixed Paraffin Embedded (FFPE) technology for reduced false positives caused by truncation are US/PCT patent pending.